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CoThis trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, was superior to
placebo, on a background of standard of care, in increasing the time to the ﬁrst occurrence of the composite endpoints of
cardiovascular (CV) death and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction (HFrEF).
Deﬁciency in sGC-derived cyclic guanosine monophosphate (cGMP) causes both myocardial dysfunction and impaired
endothelium-dependent vasomotor regulation that includes the myocardial microcirculation. Experimental studies have
suggested multiple potential beneﬁts of sGC stimulators including prevention, or even reversal, of left ventricular hy-
pertrophy and ﬁbrosis, as well as reduction of ventricular afterload through both systemic and pulmonary vasodilation.
Hence, restoration of sufﬁcient nitric oxide (NO)-sGC–cGMP signaling has been proposed as an important treatment
target in HF. Vericiguat has been shown to directly stimulate sGC and enhance sGC sensitivity to endogenous NO.
Available phase IIb data in HFrEF patients indicate vericiguat is safe and well-tolerated, and exploratory analyses indicate
that it results in a dose-dependent, clinically signiﬁcant reduction in N-terminal pro–B-type natriuretic peptide
(NT-proBNP) at the highest tested dose. VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced
Ejection Fraction) is a randomized, placebo-controlled, parallel group, multicenter, double-blind, event-driven phase 3
trial of vericiguat in subjects with HFrEF. Approximately 4,872 subjects will be randomized to evaluate the efﬁcacy and
safety of vericiguat compared with placebo on a background of standard of care. After a screening phase of up to 30
days, eligible subjects will be treated until the required number of cardiovascular deaths is observed. The estimated
median follow-up duration is approximately 18 months. All subjects will be followed until study completion to assess for
the occurrence of endpoint events. VICTORIA will establish the efﬁcacy and safety of vericiguat on cardiovascular
death and HF hospitalization in patients with HFrEF. (A Randomized Parallel-Group, Placebo-Controlled, Double-Blind,
Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efﬁcacy and Safety of the Oral sGC Stimulator
Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction [HFrEF]—VerICiguaT Global Study in Subjects
With Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534) (J Am Coll Cardiol HF 2018;6:96–104)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 http://dx.doi.org/10.1016/j.jchf.2017.08.013
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AND ACRONYM S
CV = cardiovascular
HF = heart failure






pGC = particulate guanylate
cyclase
sGC = soluble guanylate
cyclaseH eart failure (HF) with reduced ejection frac-tion (HFrEF) constitutes a major globalpublic health challenge. Not only does HF
represent a substantial cause of morbidity and mor-
tality, but it also imposes a major economic burden
on the health care system. Although advances in
care have reduced mortality and morbidity, the prog-
nosis for these patients remains poor. It is estimated
that only 50% of patients survive 5 years beyond their
initial diagnosis. Moreover, repeated hospitalizations
and the need for supplemental parenteral emergent
therapy provoked by frequent exacerbations signal
both an impaired quality of life and an even worse
prognosis. Notwithstanding the optimal use of
evidence-based HFrEF therapy, these clinical realities
represent both unmet needs and opportunities for ad-
vancements in care. Hence, as articulated in the 2013
American College of Cardiology/American Heart As-
sociation guidelines, “Future research will need to
focus on novel pharmacological therapies, especially
for hospitalized HF” (1).
Vericiguat (Central Illustration) is a novel soluble
guanylate cyclase (sGC) stimulator optimized for
once-daily dosage in development for chronic HF.
Beyond its vasodilatory properties, low-dose sGC
stimulation in preclinical models has been shown to
also have direct antiﬁbrotic effects, improving
myocardial remodeling and diastolic relaxation in the
absence of any hemodynamic effects. The sGC is the
intracellular receptor for its endogenous ligand nitric
oxide (NO). NO is generated in endothelial cells upon
physiologic stimuli such as laminar blood ﬂow shear
forces as well as within the endocardium. NO diffuses
to neighboring tissues such as vascular or cardiac
muscle cells and stimulates sGC to generate cyclic
guanosine monophosphate (cGMP) in these cells (2).
The sGC-mediated production of cGMP is essential for
normal cardiac and vascular function (3–5). In HFfor Abbott Vascular, AstraZeneca, Bristol-Myers Squibb, Gilead, Janssen, P
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tive oxygen species have been shown to
reduce NO bioavailability, resulting in rela-
tive sGC deﬁciency and a reduction in cGMP
synthesis (2). Reduced sGC activity associ-
ated with coronary microvascular dysfunc-
tion, cardiomyocyte stiffness, interstitial
ﬁbrosis, and ultimately, myocardial dysfunc-
tion has been suggested as a driving factor
behind the progression of myocardial
dysfunction in HF (6–8). These mechanisms
are not directly addressed by currently
established therapies that modulate neuro-
humoral blockade and afterload reduction.
Direct NO-independent sGC stimulation is hypothe-
sized to offer a novel approach to address the relative
cGMP deﬁcit in HF, and the sGC stimulator, ver-
iciguat, was developed for this purpose (9).
Preclinical and clinical studies with other sGC stim-
ulators have suggested that vericiguat is well suited
for development as an HF agent based on its direct
vasodilatory properties, as well as on its targeting
myocardial compliance, diastolic function, endothe-
lial function to improve vasotonal regulation, ven-
tricular–arterial coupling, and cardiac reserve in HF
(10). Clinical support for the concept of the sGC
stimulator mechanism in HFrEF was established with
riociguat in the LEPHT (Left Ventricular Systolic
Dysfunction Associated With Pulmonary Hyperten-
sion Riociguat Trial) study (11), which showed that
sGC stimulators are both well tolerated in patients
with advanced systolic left ventricular dysfunction
and secondary pulmonary hypertension due to HF
and improve cardiac index, quality of life, and pul-
monary and systemic vascular resistance at 16 weeks
of treatment. These hemodynamic improvements
occurred in the absence of changes in heart rate,
blood pressure, and the primary endpoint pulmonaryﬁzer, and GlaxoSmithKline. Dr. Butler has received
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CENTRAL ILLUSTRATION Restoration of Sufﬁcient
sGC-cGMP Signaling as Novel Target in HF
Armstrong, P.W. et al. J Am Coll Cardiol HF. 2018;6(2):96–104.
Endothelial dysfunction due to oxidative stress and inﬂammation reduces nitric oxide
bioavailability leading to insufﬁcient activation of sGC. The resulting cGMP deﬁciency is
associated with myocardial dysfunction and impaired endothelium-dependent
vasomotor regulation (orange). Vericiguat directly stimulates sGC in a NO-independent
manner and by sensitizing the enzyme to endogenous NO (green). cGMP ¼ cyclic
guanosine monophosphate; HF ¼ heart failure; NO ¼ nitric oxide; sGC ¼ soluble
guanylate cyclase.
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patients with HF, beyond those with elevated pul-
monary artery pressure. The sGC stimulator riociguat
was approved for the treatment of pulmonary arterial
hypertension and chronic thromboembolic pulmo-
nary hypertension (12,13). Vericiguat is structurally
and pharmacologically distinct from riociguat and has
been optimized for chronic use in HF patients, allow-
ing once-a-day dosage with lower pharmacokinetic
variability. Vericiguat is also hypothesized to improve
cardiac outcomes through direct cardiac effects in
the absence of blood pressure-lowering effects.
Evidence supporting the current study emanates
from the phase IIb dose-ﬁnding study (SOCRATES-
REDUCED [SOluble guanylate Cyclase stimulatoR in
heArT failurE]) in subjects with HFrEF. In that study,
vericiguat was added to standard of care in patients
with worsening chronic HF requiring hospitalization
or intravenous (IV) diuretic treatment and increased
B-type natriuretic peptide (BNP) or N-terminal pro–B-
type natriuretic peptide (NT-proBNP) (14). Whereas
the pre-speciﬁed primary endpoint analysis
comparing the impact of the 3 pooled higher dose
groups on NT-proBNP to placebo did not reach sta-
tistical signiﬁcance, an exploratory analysis showed a
clinically signiﬁcant reduction of NT-proBNP at thehighest dose group. Although not powered for clinical
endpoints, exploratory analysis also revealed nu-
merical trends in both cardiovascular (CV) death and
HF hospitalization, as well as improved New York
Heart Association (NYHA) functional class in the 2
highest dose groups along with concurrent improve-
ment in left ventricular EF with the highest target
vericiguat dose (14). Overall, vericiguat was safe and
well tolerated relative to placebo, except for
treatment-emergent syncope and hypotension that
was more common in the 10-mg group (although this
tended to occur within the ﬁrst 2 weeks of randomi-
zation while receiving the 2.5-mg dose). These ﬁnd-
ings provide the rationale for this phase III clinical
outcome trial in HFrEF. By contrast, in another phase
2 study of HFpEF patients, vericiguat did not modify
NT-proBNP concentration but did demonstrate
improvement in quality of life metrics (15).
Bayer and Merck Sharp & Dohme (Whitehouse
Station, New Jersey) are supporting the co-
development of vericiguat in collaboration with aca-
demic partners at the Canadian Virtual Coordinating
Global Collaborative Cardiovascular Research Centre
at the University of Alberta and the Duke Clinical
Research Institute to conduct the VICTORIA (Ver-
iciguat Global Study in Subjects With Heart Failure
With Reduced Ejection Fraction) trial.
STUDY OBJECTIVES
The primary objective of the VICTORIA trial is to
determine whether vericiguat is superior to placebo
on a background of standard of care in increasing the
time to the ﬁrst occurrence of the composite endpoint
of CV death or HF hospitalization in patients with
HFrEF.
Secondary objectives are to determine whether
vericiguat is superior to placebo in increasing the
time to CV death, time to ﬁrst and subsequent HF
hospitalizations, time to ﬁrst occurrence of the com-
posite of all-cause mortality or HF hospitalization,
and time to all-cause mortality and to assess the
safety and tolerability of vericiguat.
Other exploratory objectives include comparison of
vericiguat with placebo regarding the time to ﬁrst
occurrence of the composite of HF hospitalizations or
urgent HF visits, time to ﬁrst CV hospitalizations,
total number of HF hospitalizations, and changes in
quality of life health-related summary measurements
(using Kansas City Cardiomyopathy Questionnaire
and EuroQol Group 5-Dimensional surveys) from
baseline. The relationships among treatment effect,
baseline biomarkers, and genetic variation will also
be examined.
FIGURE 1 Study Time Course and Dosage Schema for Drug Titration
HF ¼ heart failure.
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STUDY DESIGN. This is a randomized, placebo-
controlled, parallel-group, multicenter, double-
blind, event-driven trial of vericiguat in subjects
with HFrEF, to be conducted in conformance with
Good Clinical Practice. Approximately 4,872 subjects
will be randomized in a 1:1 ratio to compare the efﬁ-
cacy and safety of vericiguat with those of placebo on
a background of standard of care. After a screening
phase of up to 30 days, eligible subjects will be
treated until the required number of CV deaths is
observed. The estimated median follow-up duration
is approximately 18 months. All subjects will be
followed until study completion to assess for the
occurrence of endpoint events.
STUDY INTERVENTION. As shown in Figure 1, after
randomization, the protocol is initiated with a 2.5-mg
dose of vericiguat or matching placebo. Subjects will
then be up-titrated in a blinded fashion to 5 mg and
subsequently to the target dose of 10 mg of vericiguat
or matching placebo. This titration criterion is based
on evaluation of mean systolic blood pressure and
clinical symptoms at 2-week intervals. Following the
4-week titration phase, subjects will be evaluated
every 4 months until study completion. In order to
maximize the likelihood of titration to the 10-mg
target dose, additional efforts (at the discretion ofthe investigator) will be undertaken at every subse-
quent visit throughout the study to consider up-
titration in those subjects not reaching the target
dose, based on mean systolic blood pressure mea-
surement and safety considerations.
STUDY POPULATION. The population includes
subjects $18 years of age with chronic HF (NYHA
functional classes II to IV) and reduced EF of <45%
receiving standard of care, guided by European So-
ciety of Cardiology and American Heart Association/
American College of Cardiology heart failure guide-
lines, as well as country speciﬁc guidelines (where
they exist). Inclusion and exclusion criteria are
described in Table 1 and reﬂect experience in the
SOCRATES-REDUCED trial (14). While a similar pop-
ulation is being targeted in this phase III trial, the
inclusion window has been extended from 4 weeks to
6 months post-discharge to include a broader HF
population ranging from those initially stabilized af-
ter hospitalization or IV diuretic treatment to longer-
term stable patients after their most recent HF event.
This temporal window in the context of worsening HF
is meant to provide a broader and more representa-
tive HF patient population. Additionally, given a lack
of meaningful inﬂuence of vericiguat on blood pres-
sure in the SOCRATES-REDUCED trial, the minimal
systolic blood pressure exclusion criterion has been
lowered from 110 to 100 mm Hg.
TABLE 1 VICTORIA Trial Inclusion and Exclusion Criteria
Inclusion Criteria Main Exclusion Criteria
 Ejection fraction of <45% assessed within 12 months prior to
randomization
 Elevated natriuretic peptide levels within 30 days prior to
randomization; for patients in sinus rhythm, BNP $300 pg/ml
and for NT-proBNP $1,000 pg/ml; for those in atrial ﬁbrillation,
BNP$ 500 pg/ml; and for NT-proBNP $1,600 pg/ml*
 Prior HF hospitalization within 6 months (those >3 months
limited to 20%) or outpatient IV diuretic therapy for HF within
3 months prior to randomization
 Clinically unstable
 Systolic blood pressure <100 mm Hg
 Concurrent or anticipated use of long-acting nitrates of sGC
stimulator
 PDE5 inhibitors
 Receiving IV inotropes, an implantable LV assist device or
awaiting heart transplantation
 Correctable, complex, or clinically active cardiac comorbidity
 Prior cardiac valve intervention <3 months or coronary
revascularization <60 days
 Unable to provide informed consent
 Females of reproductive age not using an acceptable form of
contraception
*For those subjects receiving sacubitril/valsartan, NT-proBNP criteria will be applied.
BNP ¼ brain natriuretic peptide; HF¼ heart failure; IV ¼ intravenous; LV¼ left ventricle; NT-proBNP¼ N-terminal pro–B-type natriuretic peptide; PDE5¼ phosphodiesterase
type 5; sCG ¼ soluble guanylate cyclase; VICTORIA ¼ Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction.
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100STATISTICAL CONSIDERATIONS. The sample size
estimation is based on a 1:1 randomization. The
overall study-wise type I error will be controlled at
0.025 (1-sided). The study is event-driven, and
accrual is planned to occur over 30 months with a
follow-up of 9 months after the last subject is
enrolled. The sample size calculation is determined
by the CV death component of the composite primary
endpoint; the expected event rate of CV death in the
placebo group is 11% after 12 months. The relative risk
reduction with vericiguat is assumed to be 20%,
relating to a hazard ratio (HR) of 0.8. Using the log-
rank test, 782 deaths conﬁrmed by a Clinical Events
Committee (CEC) will be required to achieve 80%
power. For the placebo arm, the event rate of the
composite endpoint, that is, ﬁrst HF hospitalization
or CV death, is expected to be 23% after 12 months.
The relative risk reduction with vericiguat is also
assumed to be 20%, relating to an HR of 0.8. With a
sample size of 4,872 subjects, it is anticipated that
1,561 subjects will experience a composite primary
endpoint event resulting in an expected power of
approximately 98%. The time point of ﬁnal analysis
will be based on the number of CV deaths. The me-
dian treatment duration will be approximately 480
days. If the CV death event rate is higher than antic-
ipated, such that the median follow-up time is <10
months when 782 CV death events have been
observed, the study will continue until a median
follow-up time of 10 months has been reached.
A futility interim analysis to assess lack of efﬁcacy
is planned when approximately 50% of the primary
events are observed. An efﬁcacy interim analysis is
planned to test for the primary endpoint and the
secondary endpoint of time to CV death at the time
when approximately 75% of the CV death events are
observed. In accordance with this interim analysis,the nominal 1-sided signiﬁcance level will be 0.0241
at the ﬁnal analysis (Figure 2).
Analysis of the primary efﬁcacy endpoint will
follow the intention-to-treat principle on all subjects
randomized. This analysis will be based on results
from centrally performed blinded adjudication and
will test whether the time to the ﬁrst occurrence of
the composite endpoint is prolonged in the vericiguat
as compared to that in the placebo group. Subgroup
analysis according to standard prognostically rele-
vant baseline factors will be performed and also
include the following: baseline NT-proBNP concen-
tration by quartiles, EF of <35% versus $35%, and use
of sacubitril/valsartan therapy. Safety and tolerability
will be assessed by clinical review of all relevant
parameters including adverse events, laboratory
tests, and vital signs. Based on the aforementioned
analyses, an independent Data Safety Monitoring
Board (DSMB) supported by a statistical group
external to the trial will make recommendations to
the Executive Steering Committee chairman to
continue under the current protocol, amend the cur-
rent protocol, or terminate the study. The DSMB will
function under prespeciﬁed guidelines and proced-
ures, as described in a separate charter.
INDEPENDENT, BLINDED CLINICAL EVENT
ADJUDICATION. Initial identiﬁcation of potential
endpoints will be performed by the clinical investi-
gator and supported through the medical monitoring
process. An independent CEC will adjudicate all re-
ported deaths (CV and non-CV), CV hospitalizations,
and urgent HF visits. All personnel involved in the
adjudication process will remain blinded to treatment
allocation throughout the trial. Endpoint deﬁnitions
have been guided by the deﬁnitions proposed by the
Standardized Data Collection for Cardiovascular Tri-
als Initiative (Clinical Data Interchange Standards
FIGURE 2 Projected Study Timelines
Approximate VICTORIA trial timelines are shown from ﬁrst patient enrolled. Key study benchmarks are shown. Note that, given the
event-driven nature of the trial, these are estimates. Median treatment duration was planned forw480 days. The futility analysis will occur
when approximately 50% of the primary events have occurred. The efﬁcacy analysis is planned when 75% of the planned CV death
events have occurred (see Statistical Considerations). CV ¼ cardiovascular; DSMB ¼ Data Safety & Monitoring Board; Q ¼ quarter;
VICTORIA ¼ Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction.
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101Consortium, Austin, Texas) and as prespeciﬁed in the
CEC charter. Data adjudicated by the CEC will be used
in the ﬁnal safety and efﬁcacy analysis, unless
otherwise stated.
ADVERSE EVENTS OF SPECIAL INTEREST OR
EVENTS OF CLINICAL INTEREST. Clinical investi-
gator reports of “symptomatic hypotension” and
“syncope” (nonserious and serious adverse events)
will be followed as prespeciﬁed adverse events of
special interest (also known as an “event of clinical
interest”), using accelerated reporting timelines.
Furthermore, following available standard regulatory
guidance, signiﬁcant laboratory elevations of liver
enzymes (alanine aminotransferase or aspartate
aminotransferase $3 upper limit of normal) and
total bilirubin ($2 upper limit of normal in the
absence of alkaline phosphatase $2 upper limit of
normal) will be followed as events of clinical interest
(Guidance for Industry Drug-Induced Liver Injury:
Premarketing Clinical Evaluation; U.S. Food and Drug
Administration, Rockville, Maryland).
TRIAL ORGANIZATION. VICTORIA is co-sponsored
by Bayer and Merck Sharp & Dohme (Whitehouse
Station, New Jersey) and conducted in collaboration
with the Canadian Virtual Coordinating Global
Collaborative Cardiovascular Research Centre
(Edmonton, Alberta, Canada) and the Duke Clinical
Research Institute (Durham, North Carolina). Anexecutive committee supported by national leaders
from participating countries/regions, a DSMB, and a
CEC will oversee all aspects of the VICTORIA study
(membership provided in Online Appendix A). The
executive committee consists of international aca-
demic thought leaders as well as lead representatives
from the joint sponsors. The independent DSMB and
external DSMB statistician(s) will have access to all
data and randomization codes throughout the trial.
The sponsors and executive committee will have
equal access to and possession of the data once it is
unblinded. The executive committee will be primarily
responsible for the creation, review, and submission
of publications and presentations relating to the ma-
jor aspects of the study. The executive committee will
encourage and support other manuscript(s) for pub-
lication and presentations of similar material by the
national leaders and/or study investigators as deter-
mined appropriate.
ANCILLARY STUDIES. Additional studies will be per-
formed in conjunction with the VICTORIA trial,
including baseline and serial blood sampling for
vericiguat pharmacokinetics and their relationship to
efﬁcacy. The VICTORIA biomarkers and pharmacoge-
nomics substudies are designed with the pre-speciﬁed
goal of distinguishing genomic variants and soluble
protein biomarkers that modulate and predict the
safety and efﬁcacy of vericiguat in the treatment of










T1 Mapping (MOLLI) (pre- and post Gd-contrast)
T2 Mapping
Delayed contrast enhancing imaging
Imaging Parameters
Left ventricular volume, mass, structure and function
Right ventricular volumes, structure, and function
Left and right atrial volumes and function
Strain analyses (LV: longitudinal, radial and circumferential; LA strain)
Valvular function
Diastolic function, ﬁlling, and compliance
Systolic pulmonary artery pressure
Left ventricular mass
Extracellular volume, focal ﬁbrosis
Edema
LV coupling and external work
Gd ¼ gadolinium; LA ¼ left atrium; LV ¼ left ventricular; MOLLI ¼ Modiﬁed Look-
Locker Inversion; SSFP ¼ steady-state free precession; VICTORIA ¼ Vericiguat
Global Study in Subjects With Heart Failure With Reduced Ejection Fraction.
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102patients with chronic systolic HF. Pharmacogenomic
analyses will be executed using a genome-wide asso-
ciation study that will identify genomic loci that
modulate individual response to vericiguat, distin-
guish certain populations with heightened sensitivity
(either positive or negative) to the agent, and deter-
mine whether certain populations may beneﬁt more
preferentially from vericiguat therapy based on their
ancestral origin. The biomarker analyses will provide
insights into the potential mechanisms of therapeutic
effect in HF beyond what is currently understood
about how vericiguat affects cellular function. These
analyses will include assessment of biomarkers that
assess inﬂammation (high-sensitivity interleukin-6,
high-sensitivity C-reactive protein, and growth dif-
ferentiation factor-15), cardiac injury (high-sensitivity
cardiac troponin T), myocardial stress/stretch
(NT-proBNP, somatistatin receptor type 2), remodel-
ing (galectin-3), and the cardio-renal axis (cystatin C,
creatinine).
Comprehensive ancillary imaging studies will be
performed before ﬁrst drug exposure and after 8
months, following standardized imaging manuals and
operational procedures. To this end, all participating
sites will be trained and certiﬁed. Centralized echo-
cardiography analyses (n ¼ 900) will include standard
parameters of cardiac structure and function,
including volumes and left ventricular ejection
fraction. Additional parameters, such as strain,
measurements of right ventricle (RV) function, and
estimated pulmonary artery systolic pressure will
be assessed. Cardiac magnetic resonance imaging
analyses (n ¼ 180) will include 3-dimensional (3D)
quantiﬁcation of LV mass, as well as focal (scar) and
diffuse ﬁbrosis (extracellular volume). The key aim of
the ancillary imaging substudy is to assess the effects
of 8 months’ therapy, using vericiguat versus placebo
on cardiac structure and function. Further details are
provided in Table 2.
An economic and quality-of-life study will be per-
formed in subjects enrolled in North America. Work-
ing groups in conjunction with executive committee
oversight will conduct these studies.
DISCUSSION
Mortality and morbidity remain particularly high in
patients with HFrEF who require hospitalization or IV
diuretic treatment for HF. Moreover, temporary
intravenous application of novel drugs upon hospi-
talization when added to accepted therapy for wors-
ening HF have failed to improve long-term outcomes
(16). Hence, continued long-term treatment with
novel compounds such as sacubitril/valsartan addedto available standard of care for patients with HFrEF
show promise by improving outcomes in these pa-
tients (17). In HF there is disruption of NO-sGC–cGMP
signaling related in part to impaired production of NO
or its excessive degradation (18). Further negative
repercussions modulated through a different
pathway relate to inadequate release of atrial and B-
type natriuretic peptides or release of their abnormal
derivatives as ligands of extracellular pGC, thereby
exacerbating HF. To overcome the presumed deﬁ-
ciency in sGC-derived cGMP in HF, generation of
cGMP by guanylate cyclases has been previously
attempted through the addition of nitrates or indi-
rectly by inhibition of phosphodiesterase type-5
(PDE5), slowing the degradation of cGMP.
Given the limitations of these strategies,
including the development of nitrate tolerance, the
limited PDE5 expression in cardiac tissues, and the
dependence on endogenous cGMP, neither have
proven efﬁcacious for the chronic treatment of HF.
The mechanism of action of vericiguat is distinct
from that of sacubitril’s inhibition of neprilysin.
Vericiguat interacts directly with sGC, the intracel-
lular receptor for endogenous nitric oxide, which
stimulates cGMP production. In contrast, sacubitril
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HFrEF
constitutes a major global public health challenge. Deﬁciency in
sGC-derived cGMP causes both myocardial dysfunction and
impaired endothelium-dependent vasomotor regulation, and
restoration of sufﬁcient sGC–cGMP signaling has been proposed
as a potentially important target in HF therapy. The VICTORIA
trial will establish the efﬁcacy and safety of vericiguat, a soluble
guanylate cyclase stimulator, in increasing the time to the
composite endpoint of cardiovascular death or hospitalization
in patients with HFrEF.
TRANSLATIONAL OUTLOOK: Successful demonstration of
the efﬁcacy and safety of vericiguat will address a key unmet
need for a new pharmacological treatment of patients with
HFrEF. Additional supporting ancillary studies will help to
elucidate an understanding of the observed clinical outcomes.
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103affects the particulate guanylate cyclase (pGC), the
membrane-bound receptor for natriuretic peptides,
indirectly by inhibition of the degradation of the
endogenous ligand. Hence, both the receptor type as
well as the molecular mode of action are different.
Vericiguat has a dual mode of action to help correct
the relative cGMP deﬁciency observed in advanced
forms of HF. It sensitizes sGC to endogenous NO by
stabilizing the NO–sGC binding. It also directly
stimulates sGC by a different binding site, inde-
pendent of NO. sGC stimulation through vericiguat
leads to an increase in intracellular cGMP in cardiac
myocytes and vascular smooth muscle cells affecting
directly both myocardial function and vascular tone.
In contrast, sacubitril inhibition primarily effects
pGC receptor, resulting in an increase in extracel-
lular cGMP, dependent on the endogenous levels of
natriuretic peptides (19).
STUDY LIMITATIONS. Activators of these 2 distinct
signaling pathways are expected to have nonredun-
dant effects owing to the intracellular compartmen-
tation of cGMP-dependent effectors (20). Preclinical
studies as well as early development studies further
document the additive pharmacodynamics effect of
these 2 mechanisms. Therefore, although the poten-
tial for hypotension with concomitant blood
pressure-lowering drugs also includes sacubitril/val-
sartan, the combination of vericiguat with neprilysin
inhibitors is expected to be safe and well tolerated.
Instead, coactivation of both distinct GCs has been
postulated as potential beneﬁcial therapeutic strategy
in HF (21).
CONCLUSIONS
The VICTORIA trial constitutes a novel, major indus-
trial and academic collaboration directed toward
meeting clinical needs of high-risk HFrEF patients
with progression of chronic HF despite optimizedstandard of care therapy. It represents the ﬁrst
phase III study of vericiguat, a novel sGC stimulator
designed to enhance outcomes in this disorder.
Additional supporting ancillary studies will help to
elucidate an understanding of the clinical outcomes.
A substantial international effort is now under way
to recruit appropriate patients. The ﬁrst patient
was randomized on September 23, 2016. Study
enrollment is expected to be completed before the
end of 2019.
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